26 August 2019 - Zensun announced that the investigation of Neucardin, its recombinant human neuregulin-1 fragment, has received fast track designation from the U.S. FDA for the potential treatment of chronic heart failure.
Neucardin, the lead drug candidate from the company’s cardiac therapy program, was also recently granted “priority review” for its conditional approval application in China by the National Medical Products Administration.
Neucardin is a recombinant human neuregulin-1 (rhNRG-1) fragment peptide of the neuregulin-1 beta 2 alpha isoform (rhNRG-1β2α), which is being developed as a parenteral (intravenous or subcutaneous) agent for the treatment of chronic heart failure with reduced ejection fraction.